Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07665060 · ClinicalTrials.gov registry record
HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy
A clinical trial, sponsored by NYU Langone Health.
- Active
- Registry status
- 6,100
- Enrollment target
NCT07665060: Active study, sponsored by NYU Langone Health.
NCT07665060 is a clinical trial that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 6,100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07665060 is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 6,100 participants
- Enrollment target
Study Summary
The purpose of this study is to establish a proof-of-concept for whether rapid test can detect viral rebounds that occurred within a retrospective time window among PLHIV receiving ART in the United States and sub-Saharan Africa. The objective of this study is to assess whether HIV antibody levels rise following HIV viral rebound, and the sensitivity and specificity of antibody level increases for detecting HIV viral rebounds. The investigators will conduct a retrospective matched case-control study of individuals with or without suppressed viral load on antiretroviral therapy (ART). Biobanked specimens will be tested for antibody levels.
Primary Outcome
Sensitivity of a given change in antibody levels from T1 to T3 for correctly classifying individuals as having unsuppressed or suppressed VL at T2. Unsuppressed VL will be defined as VL \>500 copies/mL.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,100 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2031-03-31 |
What the registry record for NCT07665060 still lists
NCT07665060 is an observational study that tracks outcomes without assigning an intervention. Its 6,100 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07665060 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07665060 about?
NCT07665060 is a clinical study titled "HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy". The purpose of this study is to establish a proof-of-concept for whether rapid test can detect viral rebounds that occurred within a retrospective time window among PLHIV receiving ART in the United States and sub-Saharan Africa. The objective of this study is to assess whether HIV antibody levels ...
What is the current status of trial NCT07665060?
This trial is currently active not recruiting. The enrollment target is 6,100 participants. The study started on 2026-04-01. Estimated completion is 2031-03-31.
Who is sponsoring clinical trial NCT07665060?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT06304168 · 6,150 participants
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
- NCT05884190 · 6,030 participants · NA
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI